CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) indication : management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity
The CADTH Canadian Drug Expert Committee recommends that crelizumab be reimbursed for the management of adult patients with early PPMS as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity, if the following criteria and c...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2018, April 30, 2018
|
| Edition: | Version: 1.0 |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee recommends that crelizumab be reimbursed for the management of adult patients with early PPMS as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity, if the following criteria and conditions are met. Clinical criteria: therapy may be initiated if the patient: is between 18 and 55 years old; has a confirmed diagnosis of PPMS (based on McDonald criteria 2010), with an Expanded Disability Status Scale (EDSS) score between 3.0 and 6.5; a score of at least 2.0 on the Functional Systems scale for the pyramidal system due to lower extremity findings; and a disease duration of less than 15 years for those with an EDSS greater than 5.0 or less than 10 years for those with an EDSS of 5.0 or less. Treatment should be discontinued for patients with an EDSS score of equal to or greater than 7.0 |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (8 pages) |